匹兹堡睡眠质量指数
艾普沃思嗜睡量表
安慰剂
心率
医学
警觉
心情
可视模拟标度
血压
物理疗法
随机对照试验
麻醉
内科学
睡眠质量
多导睡眠图
精神科
失眠症
呼吸暂停
病理
替代医学
作者
Shalini Srivastava,Mark Mennemeier,Jayesh Chaudhary
标识
DOI:10.1080/07315724.2020.1753129
摘要
Objective: The present randomized, placebo-controlled study aimed to assess the long-term safety and perceivable mental acuity benefits of EnXtra® in healthy individuals.Methods: Study participants were administered EnXtra® with or without caffeine for a period of 12 weeks. The cardiovascular safety was evaluated by assessing change in QT interval, blood pressure and heart rate. Further, other efficacy variables evaluated were change in perceived alertness and calmness by Bond and Lader mood scales, Sleep disturbance by Pittsburgh sleep quality Index and daytime sleepiness by Epworth sleepiness scale.Results: None of the study group showed any significant change in the ECG or haemodynamic parameters as compared to baseline (p > 0.05). Post consumption, alertness and calmness scores were significantly increased in the EnXtra®, and EnXtra® plus caffeine group (p < 0.001) as compared to placebo. Daytime sleep scores decreased in the EnXtra® group however change was not significant. Sleep quality remained undisturbed in all three arms.Conclusion: The findings demonstrated the psychostimulant efficacy of EnXtra® with no safety concerns on long-term usage.
科研通智能强力驱动
Strongly Powered by AbleSci AI